Combined modality therapy of esophageal cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 9, 2008, Pages 851-860

  Juergens, Rosalyn A ^a   Forastiere, Arlene ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chemoradiotherapy; Chemotherapy; Esophageal cancer; Neoadjuvant

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX; TAXANE DERIVATIVE; VINBLASTINE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; ESOPHAGUS SURGERY; HUMAN; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PREOPERATIVE CARE; PROGNOSIS; REVIEW;

EID: 56049101174     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0063     Document Type: Review

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
3. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008;98:547-557.
4. Kaushik N, Khalid A, Brody D, et al. Endoscopic ultrasound compared with laparoscopy for staging esophageal cancer. Ann Thorac Surg 2007;83:2000-2002.
5. Medical Research Counsil Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359:1727-1733.
6. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6:659-668.
7. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-1984.
8. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-1598.
9. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627.
10. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-1174.
11. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006; CD002092.
12. Chiu PW, Chan AC, Leung SF, et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 2005;9:794-802.
13. Arnott SJ, Duncan W, Kerr GR, et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother Oncol 1992;24:108-113.
14. Gignoux M, Roussel A, Paillot B, et al. The value of preoperative radiotherapy in esophageal cancer results of a study of the E.O.R.T.C. World J Surg 1987;11:426-432.
15. Launois B, Delarue D, Campion JP, Kerbaol M. Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet 1981;153:690-692.
16. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16:1104-1109; discussion 1110.
17. Wang M, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. Int J Radiat Oncol Biol Phys 1989;16:325-327.
18. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005; CD001799.
19. Allum WH, Fogarty PJ, Stenning SP, Langley RE. Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer. 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Florida. Abstract 9.
20. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
21. Malthaner RA, Collin S, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2006;CD001556.
22. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits ftom neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-234.
23. Thirion PG, Michiels S, Le Maitre A, et al. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma [abstract]. J Clin Oncol 2007;25 (Suppl 1):Absttact 4512.
24. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-167.
25. Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73: 1779-1784.
26. Lee JL, Park SI, Kim SB, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004;15:947-954.27 Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer. CALGB 9781. J Clin Oncol 2008;26:1086-1092.
27. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-313.
28. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multi-modal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467.
29. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925-930.
30. Doty JR, Salazar JD, Forastiere AA, et al. Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy. Ann Thorac Surg 2002;74:227-131; discussion 131.
31. Bailey SH, Bull DA, Harpole DH, et al. Outcom after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg 2003;75: 217-222; discussion 222.
32. Stahl M, Walz MK, Stuschke M, et al. Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTX) in locally advanced esophagogastric adenocarcinomas: first results of a randomized phase III trial [abstract]. J Clin Oncol 2007:25 (Suppl 1):Abstract 4511.
33. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-2317.
34. Crehange G, Maingon P, Peignaux K, et al. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102. J Clin Oncol 2007;25:4895-4901.
35. Rizk NP, Seshan VE, Bains MS, et al. Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol 2007;2:1117-1123.
36. Rizk NP, Venkamman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007;25:507-512.
37. Ajani JA. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol 1994;21:474-482.
38. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:1152-1160; discussion 1160.
39. Erasmus JJ, Munden RF, Truong MT, et al. Preoperative chemoradiation-induced ulceration in patients with esophageal cancer: a confounding factor m turnor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol 2006;1:478-486.
40. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797-805.
41. Ajani JA, Walsh G, Komaki R, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of die esophagus or gastroesophageal junction. Cancer 2004;100:2347-2354.
42. Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002;20:2844-2850.
43. Kleinberg L, Powell ME, Forastiere A, et al. E1201: an Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/ RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus [abstract]. J Clin Oncol 2007;25(Suppl 1): Abstract 4533.
44. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98: 2177-2183.
45. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007;25:2741-2746.
46. Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005;11:2215-2221.
47. Izzo JG, Correa AM, Wu TT, et al. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 2006;5:2844-2850.
48. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. Clin Adv Hematol Oncol 2007;5:79-81.
49. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizurnab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-5206.